Drug intelligence / Profile preview

PTX-252

Development stage: Unknown
Lead developer: Pleco Therapeutics
Modality: Small Molecules
Administration: Intravenous

Overview

PTX-252 is a novel small molecule drug developed to increase the sensitivity of cancer cells to chemotherapy, specifically for the treatment of acute myeloid leukemia (AML). Its mechanism involves removing toxic heavy metals from the tumor microenvironment, which improves the functioning of the tumor suppressor protein p53 and thereby increases cancer cell responsiveness to chemotherapy. PTX-252 is administered intravenously and has been granted Orphan Drug Designation by the FDA for AML. The drug was co-developed by Pleco Therapeutics and Hyloris Pharmaceuticals, with clinical development led by Pleco Therapeutics[1][2][4][5][6].

Other names: Plecoid Agent

Targets

TP53 (Cellular Tumor Antigen p53 R175H)

Beyond the preview

Go deeper on PTX-252.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTX-252.

Explore the full profile